©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 21, 2012; 18(11): 1229-1234
Published online Mar 21, 2012. doi: 10.3748/wjg.v18.i11.1229
Published online Mar 21, 2012. doi: 10.3748/wjg.v18.i11.1229
Table 5 Side effects and adverse reactions
| Answer options | Percentage (n) |
| None | 64.1 (50) |
| Antibodies to infliximab | 17.9 (14) |
| Infusion reaction or delayed hypersensitivity reaction | 16.7 (13) |
| Worsening ulcerative colitis | 14.1 (11) |
| Infection | 12.8 (10) |
| Headache | 9.0 (7) |
| Arthralgia | 9.0 (7) |
| Development of autoimmune antibodies (e.g., antinuclear antibodies, anti-dsDNA antibodies) | 5.1 (4) |
| Other | 2.6 (2) |
| Profound anemia | 1.3 (1) |
| Oncologic process | 0 (0) |
| Neurologic event (e.g., neuritis, neuropathy) | 0 (0) |
- Citation: Nattiv R, Wojcicki JM, Garnett EA, Gupta N, Heyman MB. High-dose infliximab for treatment of pediatric ulcerative colitis: A survey of clinical practice. World J Gastroenterol 2012; 18(11): 1229-1234
- URL: https://www.wjgnet.com/1007-9327/full/v18/i11/1229.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i11.1229